Acumen Pharmaceuticals, Inc. (ABOS)Healthcare | Biotechnology | Newton, United States | NasdaqGS
1.82 USD
-0.20
(-10.149%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 1.83 +0.01 (0.826%) ⇧ (Oct. 13, 2026, 4:23 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:32 a.m. EDT
The investment case for Acumen Pharmaceuticals is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. The stock has lost over 83% of its value over the last four years, with every single year in that window posting negative returns. This is not a temporary correction; it is a structural failure where the market has repeatedly rejected the company's value proposition. Fundamentally, the business is bleeding cash with negative free cash flow, negative operating cash flow, and a return on equity of -120%. The balance sheet, while technically liquid, supports a company that is burning through capital without generating revenue or profit. Analyst consensus is a 'strong buy' with a target price of $7.60, but this ignores the reality that the stock trades at a forward P/E of negative infinity because earnings are deeply negative. The options market confirms this pessimism, with traders aggressively buying puts and selling calls at strikes far above the current price, betting on further collapse. There is no catalyst visible in the data to reverse this trend, making this a dangerous speculative vehicle rather than an investment opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.181985 |
| AutoETS | 0.195410 |
| AutoTheta | 0.195647 |
| AutoARIMA | 0.195798 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 9.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.178 |
| Excess Kurtosis | -1.34 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 55.264 |
| Market Cap | 131,255,880 |
| Forward P/E | -1.27 |
| Beta | 0.33 |
| Website | https://acumenpharm.com |
As of Oct. 10, 2026, 6:32 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with heavy concentration in out-of-the-money strikes (e.g., $5.00 puts showing new volume flow exceeding existing open interest). Call activity is negligible, limited mostly to ATM anchors, while put writers are accumulating significant exposure at strikes far above the current price, indicating a strong consensus expectation of further decline.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.13304722 |
| Address1 | 1,210-1220 Washington St. |
| Address2 | Suite 210 |
| All Time High | 26.98 |
| All Time Low | 0.855 |
| Ask | 2.35 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 703,690 |
| Average Daily Volume3 Month | 437,896 |
| Average Volume | 437,896 |
| Average Volume10Days | 703,690 |
| Beta | 0.332 |
| Bid | 1.44 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.792 |
| City | Newton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.815 |
| Current Ratio | 2.466 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.0 |
| Day Low | 1.81 |
| Debt To Equity | 55.264 |
| Display Name | Acumen Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,536,000 |
| Earnings Call Timestamp Start | 1,786,536,000 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -105,367,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.641 |
| Enterprise Value | 67,529,912 |
| Eps Current Year | -1.5891 |
| Eps Forward | -1.43278 |
| Eps Trailing Twelve Months | -1.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5976 |
| Fifty Day Average Change | -0.7825999 |
| Fifty Day Average Change Percent | -0.30127808 |
| Fifty Two Week Change Percent | -13.304722 |
| Fifty Two Week High | 3.6 |
| Fifty Two Week High Change | -1.7849998 |
| Fifty Two Week High Change Percent | -0.4958333 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 0.31500006 |
| Fifty Two Week Low Change Percent | 0.21000004 |
| Fifty Two Week Range | 1.5 - 3.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,146,200,000 |
| Float Shares | 37,045,976 |
| Forward Eps | -1.43278 |
| Forward P E | -1.2667681 |
| Free Cashflow | -56,503,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Fullday Change | -0.18999994 |
| Fullday Change Percent | -9.405938 |
| Fullday Price | 1.83 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -86,787,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.067930005 |
| Held Percent Institutions | 0.66592 |
| Implied Shares Outstanding | 72,317,285 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-01 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts. |
| Long Name | Acumen Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 131,255,880 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_8539521 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -105,044,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 166,691,341 |
| Number Of Analyst Opinions | 5 |
| Open | 2.0 |
| Operating Cashflow | -91,788,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 344 4190 |
| Post Market Change | 0.014999986 |
| Post Market Change Percent | 0.82644546 |
| Post Market Price | 1.83 |
| Post Market Time | 1,791,923,006 |
| Previous Close | 2.02 |
| Price Eps Current Year | -1.142156 |
| Price Hint | 4 |
| Price To Book | 2.2916667 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.379 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.20499992 |
| Regular Market Change Percent | -10.148511 |
| Regular Market Day High | 2.0 |
| Regular Market Day Low | 1.81 |
| Regular Market Day Range | 1.81 - 2.0 |
| Regular Market Open | 2.0 |
| Regular Market Previous Close | 2.02 |
| Regular Market Price | 1.815 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 645,309 |
| Return On Assets | -0.45769 |
| Return On Equity | -1.20505 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,317,285 |
| Shares Percent Shares Out | 0.042600002 |
| Shares Short | 3,079,512 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,163,185 |
| Short Name | Acumen Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.061100002 |
| Short Ratio | 6.26 |
| Source Interval | 15 |
| State | MA |
| Symbol | ABOS |
| Target High Price | 10.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.6 |
| Target Median Price | 8.0 |
| Total Cash | 110,197,000 |
| Total Cash Per Share | 1.524 |
| Total Debt | 31,646,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.506575 |
| Two Hundred Day Average Change | -0.69157505 |
| Two Hundred Day Average Change Percent | -0.2759044 |
| Type Disp | Equity |
| Volume | 645,309 |
| Website | https://acumenpharm.com |
| Zip | 2,465 |